Last Name

 First Name

 email

 

MEDICAL PROFESSIONALS

Extensive World Health Organization (WHO) standardardized Invivo tests have shown that Flu-STOP™ kills Influenza Viruses A & B and HSV1. Furthermore, the product prevents the replication of the Influenza A and B viruses. Flu-STOP™ is made from 5 kinds of traditional Chinese herbs using ultra-modern extraction technology. (all data is summarized below)

The result of almost five years of extensive clinical research & development, Flu-STOP™ is a highly effective, natural, herbal, over-the-counter (OTC), oral anti-flu spray and is a patented scientific formulation. Developed by Professor D.S. Liu, Ph.D., one of China's most eminent and respectable virologists, Flu-STOP™ began originally as an anti-SARS virus drug during the SARS epidemic in 2003. Due to its strong ant-viral properties the product was successfully used to treat SARS infected patients and prevented SARS infection and spread at several hospitals in China.

Product Safety

Long and short term animal toxicity studies conducted on the product confirm Flu-STOP™ to be safe even at 500 times the recommended human dosage. Additionally, the product has been used by over 1,000 volunteers and has been shown to be safe and highly effective.

Invivo tests

In a managed clinical study with patients who used Flu-STOP™, 82.9% had their symptoms disappear in three days or less. Furthermore, Invitro toxicity studies confirmed that Flu-STOP™ is safe.


                         Scientific Studies

Flu-STOP™ has undergone numerous scientific studies and animal and human patient clinical trials, based on strict and rigorous pharmaceutical and WHO protocols. These studies demonstrate and confirm that Flu-STOP™ kills both Influenza A & B viruses upon contact, thus preventing contraction of the flu* and, further preventing the replication of both Influenza A & B viruses. A summary of some of these studies and clinical trials is presented below:

A 153 patient placebo-controlled clinical trial of patients with Viral Respiratory Tract Infection demonstrated an 82.9% three day recovery rate in the Flu-STOP™ group compared to 19.6% in the placebo (untreated) control group (see chart below).

Notes:
1. Viral Respiratory Tract Infection includes the common cold and anginosis, etc.
2. Clinical trial patients were aged 6 to 72, with 79 males and 75 females.


Interferon
Comparative in-vivo studies on sixty Influenza-induced mice confirm Flu-STOP™’s superiority to Interferon (a leading anti-viral pharmaceutical) against the Influenza virus, offering a protection rate of 55%, compared to only 40% for Interferon, and 10% for the non-treated, control group.

In-vivo, viral inactivation studies conducted at the China Center for Disease Control (CDC) on 11 day old chick embryos injected with the Influenza A and B viruses demonstrated inactivated virus indices (EID50/0.2 ml Flu-STOP™) of greater than 106.75. The effective inactivation concentrations of Flu-STOP™ were EC50=37.1 mg/ml and EC90=77.7 mg/ml.

Anti-Bacteria
In-vivo bacteriological screening of Flu-STOP™ against the three bacterial strains known to commonly infect the human respiratory tract - H.influenza, Aureus staphylococcus and A-hemolytic streptococcus confirmed the Flu-STOP™ compound (at 45% concentration) inhibited these bacterial strains in comparison to both positive (Penicillin) and negative (NaCl) control groups.

Note: H.influenza is the main cause of epidemic meningitis.

Flu-STOP™ Mice Acute Toxicity Experiments 

Flu-STOP™ was sprayed to the oral and nasal cavity of mice to test toxicity on mice.

No mice died during the experiment period. LD50 could not be found at the designed dose. The dose to mice in this experiment was 330 times the human clinical dose.

Mice were administered Flu-STOP™ orally to test toxicity.

No mice died during the experiment period. LD50 could not be found at the designed dose. The dose to mice in this experiment was 400 times the human clinical orally taken dose.

Both experiments confirmed that Flu-STOP™ is safe to human beings as no LD50 could be found clinically.

Flu-STOP™ Rat Extended (Long Term) Toxicity Experiments 

Continued spraying Flu-STOP™ to the oral cavity of rats with minimum, medium and maximum doses twice daily for four weeks. No obvious changes with weight, viscera index, blood general index and blood biochemical index.

During the experiment period (which included 2 weeks after the 4 weeks of spraying), there were no obvious changes in rat's apparent activities, bite and sup, water drinking, weight, blood general index, blood biochemical index, viscera index (all indexes were normal), the main viscera pathological tissue, mucosa of oral cavity and mucosa of nasal cavity.

These results included the maximum dose group (100 times of human dose) and there were no obvious pathological changes as well

The results confirmed the safety of the human clinical dose.

Flu-STOP™ Allergy and Local Stimulation Experiments  

Guinea Pig Allergy Test:There were no allergenic symptoms such as scratched noses, coat erection or decompensation on guinea pigs in the Flu-STOP™ group. Meanwhile, allergenic symptoms appeared with the control group at 14 days and 21 days.

Rat Local Stimulation Test: There was no swilling or congestion on rat's mucosa oral and nasal cavity and respiratory tract tissue. The Flu-STOP™ pathological tests were the same as the positive control group. Flu-STOP™ has no stimulation to rat's mucosa and nasal cavity and laryngeal trachea.